Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed for treating common warts and external genital warts, addressing significant unmet needs in medical dermatology [3] - Verrica is developing VP-103, a second cantharidin-based product candidate for plantar warts [3] - The company has a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Event - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will participate in a fireside chat at the TD Cowen 45 Annual Health Care Conference in Boston on March 3, 2025, at 2:30 pm ET [1][2] - Participants can access a live webcast of the event through a link provided, with a replay available for 90 days post-event [2]

Core Insights - Verrica Pharmaceuticals presented promising clinical data for VP-315, an investigational therapy for basal cell carcinoma (BCC), showcasing a 97% calculated objective response rate (ORR) [1][4] - The Phase 2 study results indicate significant safety and efficacy, with 51% of tumors achieving complete histological clearance and an average tumor size reduction of 71% for residual tumors [3][4] - The company aims to position VP-315 as a non-surgical first-line treatment option for BCC, addressing a high unmet need in the market [5][9] Study Details - The Phase 2 study is a multicenter, open-label, dose-escalation trial involving 92 adult subjects with biopsy-proven BCC [6] - The study's Part 2 focused on evaluating dosing regimens and included safety and histological clearance data from 82 patients with a total of 91 tumors [2][3] - No treatment-related serious adverse events were reported, with most adverse events being mild to moderate [3] Future Plans - The company plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to discuss the development path for VP-315 [4][5] - Genomic and T-cell immune response data are expected to be available in the first quarter of 2025 [4] Market Opportunity - Basal cell carcinoma is the most common cancer in the U.S., with approximately 3-4 million diagnoses annually, highlighting a significant market opportunity for new treatment options [9] - VP-315 is viewed as a potential multi-billion-dollar commercial opportunity for the company, aiming to provide a non-invasive alternative to traditional surgical treatments [5][9]

Core Insights - Verrica Pharmaceuticals is making significant progress with its commercial strategy for YCANTH, its lead product for treating molluscum contagiosum, as evidenced by increased demand and reduced distributor inventory levels [1][11][12] - The company has successfully executed a financing strategy that has strengthened its balance sheet while focusing on operational efficiencies to preserve capital resources [2][11] - YCANTH is the first FDA-approved treatment for molluscum contagiosum, a condition affecting approximately 6 million people in the U.S., primarily children [14] Product and Market Dynamics - YCANTH is a proprietary drug-device combination that allows for precise topical dosing and is available for patients aged two years and older [2][14] - The company plans to introduce a new single applicator packaging for YCANTH in Q1 2025, aimed at enhancing convenience for healthcare providers and improving patient access [6][11] - Recent data indicates that dispensed applicator units in Q4 2024 have exceeded those of the previous quarter, despite significant cost reductions in sales and operational infrastructure [6][11] Pipeline and Future Opportunities - Verrica is advancing its pipeline, including the development of YCANTH for common warts and VP-315 for basal cell carcinoma, which could address significant unmet medical needs in dermatology [12][14] - The company has entered a worldwide license agreement with Lytix Biopharma AS to develop VP-315 for non-melanoma skin cancers [14]

Core Viewpoint - Verrica Pharmaceuticals Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $42 million before expenses [2][4]. Group 1: Offering Details - The company is offering 44,964,045 shares of common stock and pre-funded warrants for 2,235,955 shares, along with Series A and Series B warrants for 23,600,000 shares each at exercise prices of $1.0680 and $1.3350 respectively [1]. - The combined public offering price is set at $0.89 per share of common stock and accompanying warrants, or $0.8899 per pre-funded warrant [1]. - The offering is expected to close on November 22, 2024, subject to customary closing conditions [1]. Group 2: Underwriter Information - Jefferies is acting as the sole book-running manager for the offering [3]. Group 3: Company Overview - Verrica Pharmaceuticals is focused on developing medications for skin diseases requiring medical interventions, with its product YCANTH® (VP-102) being the first FDA-approved treatment for molluscum contagiosum [6]. - The company is also developing VP-103 for plantar warts and has a license agreement with Lytix Biopharma AS for VP-315 targeting non-melanoma skin cancers [6].

WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value VRCA The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi ...

- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance -  WEST CHESTER, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the acceptance of two abstracts that will be presented as posters at the Fall ...

- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to ...

NEW ORLEANS, Sept. 27, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Verrica Pharmaceuticals Inc. (NasdaqGM: VRCA). In December 2020, the Company submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for regulatory approval of its lead product, VP-102 or YCANTH, for the treatment of molluscum contagiosum, a skin disease. ...

Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 27.91%. A quarter ago, it was expected that this company would post a loss of $0.54 per share when it actually produced a loss of $0.38, delivering a surprise of 29.63%. Over the last four quarters, the compa ...